Holen Sie sich die Stockscreener-App
9.32
7.72%
-0.78
Handel nachbörslich:
9.31
-0.010
-0.11%
Schlusskurs vom Vortag:
$10.10
Offen:
$10.14
24-Stunden-Volumen:
73,018
Relative Volume:
1.17
Marktkapitalisierung:
$242.34M
Einnahmen:
$26.00M
Nettoeinkommen (Verlust:
$-219.71M
KGV:
-0.1871
EPS:
-49.8
Netto-Cashflow:
$-51.37M
1W Leistung:
-8.54%
1M Leistung:
-4.99%
6M Leistung:
-10.04%
1J Leistung:
-55.45%
1-Tages-Spanne:
$9.31
$10.27
1-Wochen-Bereich:
$9.31
$10.48
52-Wochen-Spanne:
$8.46
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Firmenname
Cartesian Therapeutics Inc
Sektor
Branche
Telefon
301-348-8698
Adresse
7495 NEW HORIZON WAY, FREDERICK
Vergleichen Sie RNAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
9.32 | 262.62M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | Wedbush | Outperform |
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-08-06 | Eingeleitet | TD Cowen | Buy |
| 2024-07-02 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2024-05-24 | Eingeleitet | Mizuho | Buy |
| 2024-04-23 | Bestätigt | H.C. Wainwright | Buy |
| 2024-04-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-18 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Bestätigt | Needham | Buy |
| 2022-06-06 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-01-26 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-10-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-10-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Herabstufung | Stifel | Buy → Hold |
| 2020-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-01-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Eingeleitet | William Blair | Outperform |
| 2018-06-27 | Eingeleitet | Janney | Buy |
| 2017-03-30 | Bestätigt | UBS | Buy |
Alle ansehen
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
Will Cartesian Therapeutics Inc. (1S70) stock enhance shareholder valueAnalyst Downgrade & Pattern Based Trade Signal System - newser.com
How to manage a losing position in Cartesian Therapeutics Inc.Weekly Stock Summary & Entry Point Confirmation Signals - newser.com
Is Cartesian Therapeutics Inc. stock entering bullish territoryWeekly Investment Report & Long-Term Safe Return Strategies - newser.com
Published on: 2025-10-10 06:07:33 - newser.com
Will earnings trigger a reversal in Cartesian Therapeutics Inc.2025 Market Sentiment & Risk Managed Trade Strategies - newser.com
Can trapped investors hope for a rebound in Cartesian Therapeutics Inc.2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Can Cartesian Therapeutics Inc. (1S70) stock expand revenue streams2025 Technical Overview & Safe Entry Zone Identification - newser.com
Applying big data sentiment scoring on Cartesian Therapeutics Inc.Share Buyback & Scalable Portfolio Growth Ideas - newser.com
Will Cartesian Therapeutics Inc. (1S70) stock outperform benchmarksJuly 2025 Intraday Action & High Yield Stock Recommendations - newser.com
Forecasting Cartesian Therapeutics Inc. price range with options dataRate Cut & Fast Entry Momentum Alerts - newser.com
How to interpret RSI for Cartesian Therapeutics Inc. stockWeekly Trend Summary & Stock Portfolio Risk Management - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Published on: 2025-10-09 04:13:52 - newser.com
Cartesian Therapeutics Inc (RNAC): What Does Valuation Ratios Tell Us? - fostersleader.com
Cartesian Therapeutics appoints June Seymour as chief accounting officer - Investing.com
What analysts say about Cartesian Therapeutics Inc 1S70 stockLow Beta Stocks & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Live market analysis of Cartesian Therapeutics Inc.Earnings Summary Report & Free Safe Capital Growth Stock Tips - newser.com
What consensus target says about Cartesian Therapeutics Inc. (1S70) stockWeekly Profit Recap & Verified Momentum Watchlists - newser.com
Cartesian Therapeutics Inc. stock trend outlook and recovery pathMarket Movement Recap & High Accuracy Swing Entry Alerts - newser.com
What macro factors could drive Cartesian Therapeutics Inc. (1S70) stock higherInflation Watch & Technical Pattern Based Buy Signals - newser.com
Cartesian Therapeutics Announces New Employment Inducement Grant - MarketScreener
Is Cartesian Therapeutics Inc a good long term investmentExit Strategy Tips & Free High Yield Portfolio Picks - earlytimes.in
Will Cartesian Therapeutics Inc. stock attract more institutional investorsJuly 2025 Opening Moves & Real-Time Buy Signal Alerts - newser.com
We Think Cartesian Therapeutics (NASDAQ:RNAC) Can Afford To Drive Business Growth - Sahm
TD Cowen Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating - 富途牛牛
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cartesian Therapeutics (RNAC) Awards Stock Options to New Employ - GuruFocus
9,700-Share Option: Cartesian Therapeutics Grants Award at $10.34, vests 25% on Oct. 2, 2026 - Stock Titan
What analysts say about Cartesian Therapeutics Inc stockHigh Beta Stocks & Rapid Capital Trading - earlytimes.in
Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cartesian Therapeutics Inc-Aktie (RNAC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| English Emily | Chief Operations Officer |
Apr 15 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
47,726 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
48,595 |
508,751 |
620,175 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
41,782 |
393,947 |
571,580 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
36,338 |
391,455 |
656,513 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
8,575 |
89,773 |
8,637,273 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
7,373 |
69,517 |
8,628,698 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
6,412 |
69,074 |
8,643,685 |
| SPRINGER TIMOTHY A | Director |
Mar 20 '25 |
Buy |
15.59 |
54,889 |
855,593 |
8,621,325 |
| SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
| SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):